Swedish Orphan Biovitrum AB (SOBI) Price & Analysis

Swedish Orphan Biovitrum AB (publ), known as Sobi, is an integrated biopharmaceutical company dedicated to the research, development, manufacturing, and sale of specialized medicines. Its operations span Europe, North America, and other international markets. Sobi primarily focuses on therapeutic areas such as haematology, immunology, and genetic and metabolic disorders. Its significant product offerings include Alprolix and Elocta, both used to treat haemophilia B and A, respectively; Doptelet for managing thrombocytopenia; Gamifant for hemophagocytic lymphohistiocytosis (HLH); Kineret, indicated for cryopyrin-associated periodic syndrome, rheumatoid arthritis, and Still's disease; Orfadin, prescribed for hereditary tyrosinaemia type-1; and Synagis, which helps prevent severe lower respiratory tract infections. Beyond these core products, the company also provides other pharmaceutical items like Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In its development efforts, Sobi produces drug substance for Pfizer's ReFacto AF/Xyntha, and is actively working on BIVV001 for haemophilia A, and Nirsevimab for respiratory syncytial virus. Furthermore, Sobi maintains a strategic alliance with Apellis Pharmaceuticals Inc. to advance pegcetacoplan, a potential treatment for multiple rare conditions, including paroxysmal nocturnal hemoglobinuria. The company's corporate headquarters are located in Solna, Sweden.